Vyne Therapeutics Inc
VYNE
View Detailed Chart
0.304USD
-0.006-1.87%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
6.02MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.87%
5 Days
-2.03%
1 Month
-8.65%
6 Months
-82.81%
Year to Date
-90.92%
1 Year
-83.99%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
3.250
Target Price
+948.39%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Growing
The company is in a growing phase, with the latest annual income totaling USD 501.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 71.62.
Fairly Valued
The company’s latest PE is -0.34, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 9.46M shares, decreasing 12.09% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 496.30K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.76.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Ticker SymbolVYNE
CompanyVyne Therapeutics Inc
CEOMr. David Domzalski
Websitehttps://vynetherapeutics.com/
Related Instruments
+0.68%
+1.38%
-2.48%
-1.57%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.44%
-0.19%
-1.18%
-2.84%
0.00%
+0.30%
-3.72%
